Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea
2. Orgovyx
3. Tak 385
4. Tak-385
5. Tak385
1. 737789-87-6
2. Tak-385
3. Orgovyx
4. Tak 385
5. 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea
6. Chembl1800159
7. P76b05o5v6
8. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
9. Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-n'-methoxy-
10. Relugolix [usan:inn]
11. Unii-p76b05o5v6
12. Tak385
13. Tak-385/tak385
14. Relugolix (jan/inn)
15. Relugolix [inn]
16. Relugolix [jan]
17. Relugolix(tak-385)
18. Relugolix [usan]
19. Relugolix [who-dd]
20. Schembl778416
21. Gtpl5586
22. Relugolix [orange Book]
23. C29h27f2n7o5s
24. Dtxsid40224167
25. Rvt-601
26. Amy27916
27. Bcp21587
28. Ex-a1083
29. Myfembree Component Relugolix
30. Tak-385; Rvt-601
31. Bdbm50347982
32. Mfcd25976856
33. S5808
34. Zinc43206033
35. Cs-5917
36. Db11853
37. Relugolix Component Of Myfembree
38. Sb16721
39. Ac-35863
40. Bs-18032
41. Hy-16474
42. N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-n'-methoxyurea
43. D10888
44. A857822
45. Ryeqo (relugolix-estradiol-norethisterone Acetate)
46. Q21099000
47. 1-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea
48. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[4,5-e]pyrimidin-6-yl]phenyl]-3-methoxyurea
49. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea;relugolix
50. 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea
Molecular Weight | 623.6 g/mol |
---|---|
Molecular Formula | C29H27F2N7O5S |
XLogP3 | 3.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 9 |
Exact Mass | 623.17624448 g/mol |
Monoisotopic Mass | 623.17624448 g/mol |
Topological Polar Surface Area | 158 Ų |
Heavy Atom Count | 44 |
Formal Charge | 0 |
Complexity | 1010 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Relugolix is indicated for the treatment of adult patients with advanced prostate cancer. In a combination product with [estradiol] and [norethindrone], relugolix is indicated for the once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer .
Approximately 56% of patients achieved castrate-level testosterone concentrations (<50 ng/dL) by day 4 of therapy and 97% of patients maintain these levels through 48 weeks of therapy. Relugolix requires once-daily oral administration to maintain the desired testosterone concentrations. Androgen deprivation therapies may prolong the QTc interval and should therefore be used with caution in patients having a high baseline risk of QTc prolongation, such as those with electrolyte abnormalities, congestive heart failure, or using other medications known to prolong the QTc interval. Based on its mechanism of action and data from animal studies, relugolix may result in fetal harm if administered to pregnant females - male patients with female partners should be advised to use effective contraception throughout therapy and for 2 weeks following cessation of therapy to prevent inadvertent fetal exposure.
Androgen Antagonists
Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)
L02BX
L - Antineoplastic and immunomodulating agents
L02 - Endocrine therapy
L02B - Hormone antagonists and related agents
L02BX - Other hormone antagonists and related agents
L02BX04 - Relugolix
Absorption
The Cmax and AUC of orally-administered relugolix increase proportionally following single doses - in contrast, with repeat dosing the AUC remains proportional to the dose while the Cmax increases greater than proportionally to the dose. Following the administration of 120mg once daily, the steady-state AUC and Cmax of relugolix were 407 ( 168) ng.hr/mL and 70 ( 65) ng/mL, respectively. The absolute oral bioavailability of relugolix is approximately 12% and the median Tmax following oral administration is 2.25 hours.
Route of Elimination
Approximately 81% of an orally administered dose was recovered in the feces, of which 4.2% was unchanged parent drug, while 4.1% of the dose was recovered in the urine, of which 2.2% remained unchanged.
Clearance
The average renal clearance of relugolix is 8 L/h with a total clearance of 26.4 L/h.
Relugolix is metabolized mainly by the CYP3A subfamily of P450 enzymes, with a smaller contribution by CYP2C8.
The average effective half-life of relugolix is 25 hours, while the average terminal elimination half-life is 60.8 hours.
The pathogenesis and progression of prostate cancer appear driven, at least in part, by the effects of testosterone. Androgen deprivation has been demonstrated to result in cell death and tumor regression in many well-differentiated prostate cancer cell lines - for this reason, androgen deprivation therapy (ADT) has become a standard in the treatment of prostate cancer, particularly in advanced disease. Testosterone production in males is carried out in the Leydig cells of testes and is stimulated by luteinizing hormone (LH), which itself is produced in the pituitary gland following the binding of gonadotropin-releasing hormone (GnRH) to corresponding GnRH receptors. Relugolix is a competitive antagonist of these GnRH receptors, thereby decreasing the release of LH and, ultimately, testosterone.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37795
Submission : 2022-12-23
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-08-05
Pay. Date : 2024-07-10
DMF Number : 39507
Submission : 2024-03-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39995
Submission : 2024-06-14
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37365
Submission : 2022-09-06
Status : Active
Type : II
Date of Issue : 2022-06-15
Valid Till : 2025-07-28
Written Confirmation Number : WC-0186
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-07-24
Pay. Date : 2024-07-08
DMF Number : 38488
Submission : 2024-07-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40544
Submission : 2024-09-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37795
Submission : 2022-12-23
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2024-08-05
Pay. Date : 2024-07-10
DMF Number : 39507
Submission : 2024-03-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39995
Submission : 2024-06-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-07-24
Pay. Date : 2024-07-08
DMF Number : 38488
Submission : 2024-07-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-08-22
Pay. Date : 2024-07-19
DMF Number : 40209
Submission : 2024-07-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39161
Submission : 2023-12-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-08-29
Pay. Date : 2024-08-08
DMF Number : 39608
Submission : 2024-03-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-10-22
Pay. Date : 2024-09-24
DMF Number : 40410
Submission : 2024-09-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40244
Submission : 2024-07-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37365
Submission : 2022-09-06
Status : Active
Type : II
Date of Issue : 2022-06-15
Valid Till : 2025-07-28
Written Confirmation Number : WC-0186
Address of the Firm : Sy No.10/G-1, Gaddapotharam (V), Jinnaram (M), Sangareddy District, Pincode 5023...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Brand Name: Orgovyx
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2024
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Launches ORGOVYX® in Canada for Prostate Cancer Treatment
Details : Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2024
Details:
Rexigo (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in India for testosterone suppression in patients with advanced prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Brand Name: Rexigo
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2024
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences Launches Rexigo
Details : Rexigo (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in India for testosterone suppression in patients with advanced prostate cancer.
Product Name : Rexigo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2024
Details:
ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Brand Name: Orgovyx
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 24, 2023
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma Announces Authorization in Canada of Orgovyx for Treatment Prostate Cancer
Details : ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2023
Details:
Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Brand Name: Orgovyx
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 23, 2023
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma Announces Authorization in Canada of ORGOVYX® (relugolix) for the Treatment of Me...
Details : Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2023
Details:
Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.
Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Myfembree
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE®
Details : Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.
Product Name : Myfembree
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2023
Details:
Sumitovant and Myovant will strengthen Myovant's two products, Orgovyx® (relugolix) and Myfembree® capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Brand Name: Orgovyx
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Sumitovant Biopharma
Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million
Deal Type: Acquisition October 03, 2023
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Sumitovant Biopharma
Deal Size : $1,700.0 million
Deal Type : Acquisition
Sumitovant Biopharma Completes Acquisition of Myovant Sciences
Details : Sumitovant and Myovant will strengthen Myovant's two products, Orgovyx® (relugolix) and Myfembree® capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : $1,700.0 million
October 03, 2023
Details:
Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Ryeqo
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sumitomo
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sumitomo
Deal Size : Inapplicable
Deal Type : Inapplicable
Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO® for Treatment of Endo...
Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Product Name : Ryeqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2023
Details:
Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Ryeqo
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of End...
Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Product Name : Ryeqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2023
Details:
Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Brand Name: Orgovyx
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2022
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Details:
MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is the first once-daily oral treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women approved by U.S. Food and Drug Administration, with a treatment duration of upto 24 months.
Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Myfembree
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2022
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is the first once-daily oral treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women approved by U.S. Food and Drug Administration, with a treatment durati...
Product Name : Myfembree
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2022
Regulatory Info :
Registration Country : Norway
Brand Name : Orgovyx
Dosage Form : Tablet, film-coated
Dosage Strength : 120 mg
Packaging : Bottle 30item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Orgovyx
Dosage Form : Filmtabl
Dosage Strength : 120mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : RX
Registration Country : USA
Brand Name : ORGOVYX
Dosage Form : TABLET;ORAL
Dosage Strength : 120MG
Packaging :
Approval Date : 2020-12-18
Application Number : 214621
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Brand Name : MYFEMBREE
Dosage Form : TABLET;ORAL
Dosage Strength : 1MG;0.5MG;40MG
Packaging :
Approval Date : 2021-05-26
Application Number : 214846
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ORGOVYX
Dosage Form : TABLET
Dosage Strength : 120MG
Packaging :
Approval Date :
Application Number : 2542137
Regulatory Info : Prescription
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : MYFEMBREE
Dosage Form : TABLET
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number : 2541742
Regulatory Info : Prescription
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RLD : Yes
TE Code :
Brand Name : ORGOVYX
Dosage Form : TABLET;ORAL
Dosage Strength : 120MG
Approval Date : 2020-12-18
Application Number : 214621
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Brand Name : MYFEMBREE
Dosage Form : TABLET;ORAL
Dosage Strength : 1MG;0.5MG;40MG
Approval Date : 2021-05-26
Application Number : 214846
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Norway
Brand Name : Orgovyx
Dosage Form : Tablet, film-coated
Dosage Strength : 120 mg
Packaging : Bottle 30item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Orgovyx
Dosage Form : Filmtabl
Dosage Strength : 120mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ORGOVYX
Dosage Form : TABLET
Dosage Strength : 120MG
Packaging :
Approval Date :
Application Number : 2542137
Regulatory Info : Prescription
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : MYFEMBREE
Dosage Form : TABLET
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number : 2541742
Regulatory Info : Prescription
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2026-01-28
US Patent Number : 8058280
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214621
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-28
Patent Expiration Date : 2037-09-29
US Patent Number : 12097198
Drug Substance Claim :
Drug Product Claim :
Application Number : 214621
Patent Use Code : U-3020
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-09-29
Patent Expiration Date : 2036-02-25
US Patent Number : 10350170
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 214621
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-02-25
Patent Expiration Date : 2026-01-28
US Patent Number : 7300935
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 214621
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-28
Patent Expiration Date : 2038-05-03
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
US Patent Number : 11793812
Drug Substance Claim :
Drug Product Claim :
Application Number : 214846
Patent Use Code : U-2360
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-05-03
Patent Expiration Date : 2037-09-29
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
US Patent Number : 11957684
Drug Substance Claim :
Drug Product Claim :
Application Number : 214846
Patent Use Code : U-3129
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-09-29
Patent Expiration Date : 2026-01-28
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
US Patent Number : 8058280
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 214846
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-28
Patent Expiration Date : 2037-09-29
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
US Patent Number : 11033551
Drug Substance Claim :
Drug Product Claim :
Application Number : 214846
Patent Use Code : U-3129
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-09-29
Patent Expiration Date : 2037-09-29
US Patent Number : 11583526
Drug Substance Claim :
Drug Product Claim :
Application Number : 214621
Patent Use Code : U-3020
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-09-29
Patent Expiration Date : 2037-09-29
US Patent Number : 10786501
Drug Substance Claim :
Drug Product Claim :
Application Number : 214621
Patent Use Code : U-3020
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-09-29
Exclusivity Code : NCE
Exclusivity Expiration Date : 2025-12-18
Application Number : 214621
Product Number : 1
Exclusivity Details :
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Exclusivity Code : I-898
Exclusivity Expiration Date : 2025-08-05
Application Number : 214846
Product Number : 1
Exclusivity Details :
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Exclusivity Code : M-289
Exclusivity Expiration Date : 2026-01-27
Application Number : 214846
Product Number : 1
Exclusivity Details :
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Exclusivity Code : NCE
Exclusivity Expiration Date : 2025-12-18
Application Number : 214846
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE
41
PharmaCompass offers a list of Relugolix API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Relugolix manufacturer or Relugolix supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Relugolix manufacturer or Relugolix supplier.
PharmaCompass also assists you with knowing the Relugolix API Price utilized in the formulation of products. Relugolix API Price is not always fixed or binding as the Relugolix Price is obtained through a variety of data sources. The Relugolix Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-, including repackagers and relabelers. The FDA regulates Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- supplier is an individual or a company that provides Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- active pharmaceutical ingredient (API) or Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- finished formulations upon request. The Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers may include Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- API manufacturers, exporters, distributors and traders.
click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- DMF (Drug Master File) is a document detailing the whole manufacturing process of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- active pharmaceutical ingredient (API) in detail. Different forms of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- DMFs exist exist since differing nations have different regulations, such as Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- DMF submitted to regulatory agencies in the US is known as a USDMF. Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USDMF includes data on Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers with USDMF on PharmaCompass.
A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- written confirmation (Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- WC) is an official document issued by a regulatory agency to a Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- manufacturer, verifying that the manufacturing facility of a Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- APIs or Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- finished pharmaceutical products to another nation, regulatory agencies frequently require a Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- WC (written confirmation) as part of the regulatory process.
click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers with NDC on PharmaCompass.
Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- GMP manufacturer or Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- GMP API supplier for your needs.
A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- CoA (Certificate of Analysis) is a formal document that attests to Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-'s compliance with Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- specifications and serves as a tool for batch-level quality control.
Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- CoA mostly includes findings from lab analyses of a specific batch. For each Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- may be tested according to a variety of international standards, such as European Pharmacopoeia (Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- EP), Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USP).